Caris Life Sciences director granted 1,600 shares

Knowles Jonathan Kenneth Charles reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 06/02/2026 - 05:43 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Knowles Jonathan Kenneth Charles reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences director Jonathan Kenneth Charles Knowles received 1,600 shares of Common Stock on May 29, 2026 as a stock grant. The shares were issued in lieu of cash compensation for his 2026 board retainer fees, based on a ten-day volume weighted average price calculation. Following this award, he directly owns 308,979 shares of Caris Life Sciences common stock.

Insider Trade Summary

Grant/Award: 1,600 shares

Grant/Award 1 txn

Insider Knowles Jonathan Kenneth Charles

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,600	$15.62	$25K

Holdings After Transaction: Common Stock — 308,979 shares (Direct)

Footnotes (1)

1. F1. Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.

Key Figures

Shares granted: 1,600 shares Reference share price: $15.62 per share Post-transaction holdings: 308,979 shares +1 more

4 metrics

Shares granted 1,600 shares Common Stock granted May 29, 2026 for 2026 board retainer

Reference share price $15.62 per share Transaction price per share used for the 1,600-share grant

Post-transaction holdings 308,979 shares Total Common Stock directly owned by Knowles after the grant

Pricing methodology period 10 trading days Average daily volume weighted average price through May 29, 2026

Key Terms

board retainer fees, volume weighted average price, grant/award acquisition

3 terms

board retainer fees financial

"Shares issued in lieu of cash compensation for 2026 board retainer fees."

volume weighted average price financial

"ten trading day average of the daily volume weighted average price per share"

The volume weighted average price (VWAP) is a way to measure the average price of a security, such as a stock, over a specific period, taking into account how many units were traded at each price. It’s similar to calculating the average cost of items bought when some are more frequently purchased than others. Investors use VWAP to assess whether a security is being bought or sold at a fair price during trading.

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Caris Life Sciences (CAI) director Jonathan Knowles report?

Jonathan Knowles reported receiving 1,600 shares of Caris Life Sciences common stock as compensation. The shares were granted instead of cash for his 2026 board retainer, reflecting routine equity-based director pay rather than an open-market purchase or sale.

How many Caris Life Sciences (CAI) shares does Jonathan Knowles hold after this grant?

After the 1,600-share stock grant, Jonathan Knowles directly holds 308,979 Caris Life Sciences shares. This filing shows his updated ownership position following the compensation award, giving a sense of his ongoing equity stake in the company as a board member.

How was the number of shares in Jonathan Knowles’ Caris Life Sciences (CAI) grant determined?

The 1,600-share grant was calculated by dividing his cash board retainer by a ten-day average share price. Specifically, the company used the ten trading day average of the daily volume weighted average price through May 29, 2026 to convert fees into stock.

Was Jonathan Knowles’ Caris Life Sciences (CAI) transaction an open-market buy or sell?

The transaction was not an open-market buy or sell; it was a stock grant. Caris Life Sciences issued 1,600 shares to Jonathan Knowles in lieu of cash for his 2026 board retainer, categorized as a grant, award, or other acquisition.

What price per share is associated with Jonathan Knowles’ Caris Life Sciences (CAI) stock grant?

The filing lists a reference price of $15.62 per Caris Life Sciences share for the 1,600-share grant. This figure reflects the pricing used in the compensation calculation rather than a trade price from an open-market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Knowles Jonathan Kenneth Charles

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TEXAS 75039

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A(1)		1,600	A	$15.62	308,979	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)